P16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: A prospective study in China

International Journal of Cancer

Volumn 134, Issue 7, 2014, Pages 1715-1724

  Liao, Guang Dong ^a,b   Sellors, John W ^c   Sun, Hai Kui ^b   Zhang, Xun ^b   Bao, Yan Ping ^b   Jeronimo, Jose ^c   Chen, Wen ^b   Zhao, Fang Hui ^b   Song, Yan ^b   Cao, Zhi ^b   Zhang, Shao Kai ^b   Xi, Ming Rong ^a   Qiao, You Lin ^b  

^a SICHUAN UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

^c PATH   (United States)

Author keywords

biomarker; cervical intraepithelial neoplasia; p16INK4A; predictive validity; prospective study

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; CANCER GRADING; CANCER GROWTH; CANCER SCREENING; CARCINOGEN TESTING; CHINA; COLPOSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; CYTOLOGY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; ARTICLE; BIOPSY; DISEASE COURSE; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; P16INK4A; PAPILLOMA VIRUS; PATHOLOGY; PREDICTIVE VALIDITY; UTERINE CERVIX TUMOR; VIROLOGY;

BIOMARKER; CERVICAL INTRAEPITHELIAL NEOPLASIA; P16INK4A; PREDICTIVE VALIDITY; PROSPECTIVE STUDY;

ADULT; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHINA; COLPOSCOPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 84892581679     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28485     Document Type: Review

References (46)

1. Vizcaino AP, Moreno V, Bosch FX, et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 2000; 86: 429-35.
2. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
3. Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204-04.
4. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
5. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer I 1993; 85: 958-64.
6. Kjaer SK, vandenBrule AJC, Bock JE, et al. Human papillomavirus-the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 1996; 65: 601-06.
7. Alani RM, Munger K,. Human papillomaviruses and associated malignancies. J Clin Oncol 1998; 16: 330-37.
8. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(ink4a) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84.
9. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741-48.
10. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16(INK4) are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001; 25: 884-91.
11. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009; 113: 18-25.
12. Moscicki AB, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010; 116: 1373-80.
13. Ovestad IT, Gudlaugsson E, Skaland I, et al. The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3. J Clin Pathol 2011; 64: 303-7.
14. Horn LC, Klostermann K,. [Precancerous lesions of the uterine cervix: morphology and molecular pathology]. Pathologe 2011; 32 (Suppl 2): 242-54.
15. Wright TC, Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007; 197: 340-5.
16. Guido R,. Guidelines for screening and treatment of cervical disease in the adolescent. J Pediatr Adolesc Gynecol 2004; 17: 303-11.
17. Agoff SN, Lin P, Morihara J, et al. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 2003; 16: 665-73.
18. Saqi A, Pasha TL, McGrath CM, et al. Overexpression of p16(INK4A) in liquid-based specimens (SurePath (TM)) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol 2002; 27: 365-70.
19. Murphy N, Ring M, Killalea AG, et al. p16(INK4A) as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep (TM) smears. J Clin Pathol 2003; 56: 56-63.
20. Sahebali S, Depuydt CE, Segers K, et al. p16(INK4a) as an adjunct marker in liquid-based cervical cytology. Int J Cancer 2004; 108: 871-76.
21. Tringler B, Gup CJ, Singh M, et al. Evaluation of p16(INK4a) and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol 2004; 35: 689-96.
22. Klaes R, Benner A, Friedrich T, et al. p16(INK4a) immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002; 26: 1389-99.
23. Bergeron C, Ordi J, Schmidt D, et al. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2010; 133: 395-406.
24. Galgano MT, Castle PE, Atkins KA, et al. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010; 34: 1077-87.
25. Darragh TM, Colgan TJ, Thomas Cox J, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013; 32: 76-115.
26. Wang SS, Trunk M, Schiffman M, et al. Validation of p16(INK4a) as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13: 1355-60.
27. Wang JL, Zheng BY, Li XD, et al. Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 2004; 10: 2407-14.
28. Negri G, Vittadello F, Romano F, et al. P16(INK4) stop expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch 2004; 445: 616-20.
29. del Pino M, Garcia S, Fuste V, et al. Value of p16(INK4a) as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. Am J Obstet Gynecol 2009; 201: 488 e1-7.
30. Ozaki S, Zen Y, Inoue M,. Biomarker expression in cervical intraepithelial neoplasia: potential progression predictive factors for low-grade lesions. Hum Pathol 2011; 42: 1007-12.
31. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013; 14: 168-76.
32. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91: 942-53.
33. Nakashima R, Fujita M, Enomoto T, et al. Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer 1999; 80: 458-67.
34. Kelley MJ, Otterson GA, Kaye FJ, et al. Cdkn2 in Hpv-positive and Hpv-negative cervical-carcinoma cell-lines. Int J Cancer 1995; 63: 226-30.
35. Hirama T, Miller CW, Wilczynski SP, et al. p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines. Mod Pathol 1996; 9: 26-31.
36. Kim JW, Namkoong SE, Ryu SW, et al. Absence of p15INK4B and p16INK4A gene alterations in primary cervical carcinoma tissues and cell lines with human papillomavirus infection. Gynecol Oncol 1998; 70: 75-9.
37. Castle PE, Schiffman M, Burk RD, et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002; 11: 1394-9.
38. Castle PE, Solomon D, Wheeler CM, et al. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 2008; 46: 2595-604.
39. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001; 25: 884-91.
40. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741-8.
41. Tsoumpou I, Valasoulis G, Founta C, et al. High-risk human papillomavirus DNA test and p16(INK4a) in the triage of LSIL: a prospective diagnostic study. Gynecol Oncol 2011; 121: 49-53.
42. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
43. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer I 2008; 100: 492-501.
44. Bulkmans NWJ, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72.
45. Meijer CJLM, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-20.
46. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.